Naarden, the Netherlands-based Forbion, a global life sciences VC firm, announced on Tuesday, that it has raised over €2B across its two newest funds — Forbion Growth Opportunities III and Forbion Ventures VII, bringing assets under management at Forbion to €5B.
Both funds exceeded their original target sizes and reached €1.2B and €890M), respectively.
Sander Slootweg, Managing Partner and co-founder of Forbion says, “I thank all our investors for their continued confidence in our ability to source and support innovative biotechs and to deliver impactful returns. With greater levels of capital, we can extend more support to our portfolio companies as they grow and seek to maximize their potential. We continue to see great opportunities to deploy capital in Europe and North America, backing talented management teams that develop novel therapeutics with the potential to impact the future of medicine.”
With the latest capital injection, the Dutch VC aims to invest in approximately 15 portfolio companies through each fund:
Forbion’s Growth Opportunities Fund III: It is focused on investing primarily in European as well as North American later-stage biopharma companies developing novel therapies in areas of high medical need.
Forbion Ventures Fund VII: This fund will build a portfolio of innovative therapeutics-focused biotechs, both existing companies as well as NewCos, (co-) founded by Forbion, created around assets sourced from pharma or academic institutions, or around proven management teams.
Robbert van de Griendt, General Partner, Investor Relations and Impact says, “We are delighted to have achieved this record fundraising against a backdrop of volatile market conditions. The strong demand we have seen from both existing and new investors is directly related to our strong and consistent historical returns as well as an impressive string of recent exits and also reflects investors’ conviction in our specialist investment strategy and in the positive fundamentals of our sector.”
Currently, the VC firm has 58 active investments and has led or co-led 88 per cent of the initial investment rounds for the 26 portfolio companies across Forbion Growth Opportunities Fund II and Forbion Ventures Fund VI.
Forbion: Global life sciences VC firm
Forbion invests in innovative biotech companies, managing approximately €5B across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.
In addition, the company utilises its biotech expertise beyond human health to address ‘planetary health’ challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.
Since its launch over two decades ago, the company has made 128 investments.
The Dutch VC’s portfolio companies have contributed to advancing medical science and innovation by developing breakthrough therapies, pioneering new technologies like gene and immune therapies, and publishing 256 scientific papers.
At the end of 2023, active portfolio companies reported a total of 129 drug programs under development and/or in discovery, and 80% of drug programs were ‘disease-modifying’, in line with Forbion’s focus on enabling the development of novel therapeutics in critical areas of unmet medical need.
The firm is a signatory to the United Nations Principles for Responsible Investment. The company operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
01
These are the top UK-based PR agencies for startups and scale-ups in 2025